CN106727615A - A kind of Western medicine compound for treating the infection of the upper respiratory tract - Google Patents
A kind of Western medicine compound for treating the infection of the upper respiratory tract Download PDFInfo
- Publication number
- CN106727615A CN106727615A CN201611171805.8A CN201611171805A CN106727615A CN 106727615 A CN106727615 A CN 106727615A CN 201611171805 A CN201611171805 A CN 201611171805A CN 106727615 A CN106727615 A CN 106727615A
- Authority
- CN
- China
- Prior art keywords
- parts
- infection
- respiratory tract
- western medicine
- upper respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of Western medicine compound for treating the infection of the upper respiratory tract, the Western medicine compound of the treatment infection of the upper respiratory tract is according to the primary raw material of weight portion：20 30 parts of trilobatin, 10 15 parts of aspirin, 5 13 parts of β acetoxyl group isovaleryls Alkannin, 8 14 parts of cefathiamidine, 27 35 parts of allicin, 68 parts of the gloomy glycosides B of Bali, 49 parts of pot marigold glycosides E, 16 19 parts of Swertianolin, 26 parts of donaxine, loose 26 parts of ester alcohol diglucoside.Medicine of the present invention is strictly selected material composition according to the understanding mechanism of the infection of the upper respiratory tract, so as to reach the purpose of comprehensive rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Western medicine compound for treating the infection of the upper respiratory tract.
Background technology
The infection of the upper respiratory tract refers to the general name from nasal cavity to the acute inflammation between throat, is most common infectious disease
Disease.Caused by virus more, after bacterium infection often infects secondary to virus.The sick four seasons, any age can fall ill, by containing
The virulent spittle, droplet, or through pollute apparatus propagated.Motherland's medical science to infectious disease, particularly to respiratory tract infection
The understanding of disease and preventing and treating are with a long history.Early in before more than 2,000 years, Han dynasty Zhang Zhongjing just has related discussion to go out preventing and treating side's medicine side by side.Mesh
Although the Chinese patent drug species of preceding in the market treatment infection of the upper respiratory tract disease is various, presence such as dosage is big, the term of validity
The inapparent problem of short, curative effect.
Therefore, it is badly in need of a kind of suitable good effect of research and development, speed is fast, price is low, the Western medicine compound that has no toxic side effect.
The content of the invention
It is an object of the invention to provide a kind of Western medicine compound for treating the infection of the upper respiratory tract, to solve above-mentioned background skill
The problem proposed in art.
To achieve the above object, the present invention provides following technical scheme：
A kind of Western medicine compound for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：Trilobatin 20-30
Part, aspirin 10-15 parts, β -5-13 parts of acetoxyl group isovaleryl Alkannin, cefathiamidine 8-14 parts, allicin 27-35 parts,
6-8 parts of Bali gloomy glycosides B, 4-9 parts of pot marigold glycosides E, Swertianolin 16-19 parts, donaxine 2-6 parts, loose ester alcohol diglucoside
2-6 parts.
As further scheme of the invention：The Western medicine compound of the treatment infection of the upper respiratory tract, according to weight portion
Primary raw material is：Trilobatin 24-27 parts, aspirin 12-15 parts, β -7-12 parts of acetoxyl group isovaleryl Alkannin, cephalo sulphur
Amidine 10-12 parts, allicin 29-31 parts, 6-8 parts of Bali gloomy glycosides B, 4-9 parts of pot marigold glycosides E, Swertianolin 16-19 parts, giantreed
Alkali 2-6 parts, loose 2-6 parts of ester alcohol diglucoside.
As further scheme of the invention：The Western medicine compound of the treatment infection of the upper respiratory tract, according to weight portion
Primary raw material is：It is 26 parts of trilobatin, 14 parts of aspirin, β -10 parts of acetoxyl group isovaleryl Alkannin, 11 parts of cefathiamidine, big
7 parts of the gloomy glycosides B of 30 parts of allicin, Bali, 7 parts of pot marigold glycosides E, 18 parts of Swertianolin, 4 parts of donaxine, loose ester alcohol diglucoside 4
Part.
A kind of preparation method of the Western medicine compound for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
The gloomy glycosides B of acyl Alkannin, cefathiamidine, allicin, Bali, pot marigold glycosides E, Swertianolin, donaxine, loose ester alcohol glucosulfone
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4-8min, RSD≤5% is controlled, after mixing
Compressing tablet and low temperature drying, at 4-8 DEG C, packaging obtains final product the Western medicine compound of the treatment infection of the upper respiratory tract to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of the infection of the upper respiratory tract, complete so as to reach
The purpose of face rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of Western medicine compound for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：20 parts of trilobatin, Ah
10 parts of a woods of department, β -5 parts of acetoxyl group isovaleryl Alkannin, 8 parts of cefathiamidine, 27 parts of allicin, 6 parts of the gloomy glycosides B of Bali, gold
4 parts of small cup flower glycosides E, 16 parts of Swertianolin, 2 parts of donaxine, loose 2 parts of ester alcohol diglucoside.
A kind of preparation method of the Western medicine compound for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
The gloomy glycosides B of acyl Alkannin, cefathiamidine, allicin, Bali, pot marigold glycosides E, Swertianolin, donaxine, loose ester alcohol glucosulfone
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 4 DEG C, packaging obtains final product the Western medicine compound of the treatment infection of the upper respiratory tract to temperature control.
Embodiment 2
A kind of Western medicine compound for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：24 parts of trilobatin, Ah
12 parts of a woods of department, β -7 parts of acetoxyl group isovaleryl Alkannin, 10 parts of cefathiamidine, 29 parts of allicin, 6 parts of the gloomy glycosides B of Bali, gold
4 parts of small cup flower glycosides E, 16 parts of Swertianolin, 2 parts of donaxine, loose 2 parts of ester alcohol diglucoside.
A kind of preparation method of the Western medicine compound for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
The gloomy glycosides B of acyl Alkannin, cefathiamidine, allicin, Bali, pot marigold glycosides E, Swertianolin, donaxine, loose ester alcohol glucosulfone
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 4 DEG C, packaging obtains final product the Western medicine compound of the treatment infection of the upper respiratory tract to temperature control.
Embodiment 3
A kind of Western medicine compound for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：26 parts of trilobatin, Ah
Department 14 parts of a woods, β -10 parts of acetoxyl group isovaleryl Alkannin, 11 parts of cefathiamidine, 30 parts of allicin, 7 parts of the gloomy glycosides B of Bali,
7 parts of pot marigold glycosides E, 18 parts of Swertianolin, 4 parts of donaxine, loose 4 parts of ester alcohol diglucoside.
A kind of preparation method of the Western medicine compound for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
The gloomy glycosides B of acyl Alkannin, cefathiamidine, allicin, Bali, pot marigold glycosides E, Swertianolin, donaxine, loose ester alcohol glucosulfone
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 6min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 6 DEG C, packaging obtains final product the Western medicine compound of the treatment infection of the upper respiratory tract to temperature control.
Embodiment 4
A kind of Western medicine compound for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：27 parts of trilobatin, Ah
Department 15 parts of a woods, β -12 parts of acetoxyl group isovaleryl Alkannin, 12 parts of cefathiamidine, 31 parts of allicin, 8 parts of the gloomy glycosides B of Bali,
9 parts of pot marigold glycosides E, 19 parts of Swertianolin, 6 parts of donaxine, loose 6 parts of ester alcohol diglucoside.
A kind of preparation method of the Western medicine compound for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
The gloomy glycosides B of acyl Alkannin, cefathiamidine, allicin, Bali, pot marigold glycosides E, Swertianolin, donaxine, loose ester alcohol glucosulfone
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 8 DEG C, packaging obtains final product the Western medicine compound of the treatment infection of the upper respiratory tract to temperature control.
Embodiment 5
A kind of Western medicine compound for treating the infection of the upper respiratory tract, be according to the primary raw material of weight portion：30 parts of trilobatin, Ah
Department 15 parts of a woods, β -13 parts of acetoxyl group isovaleryl Alkannin, 14 parts of cefathiamidine, 35 parts of allicin, 8 parts of the gloomy glycosides B of Bali,
9 parts of pot marigold glycosides E, 19 parts of Swertianolin, 6 parts of donaxine, loose 6 parts of ester alcohol diglucoside.
A kind of preparation method of the Western medicine compound for treating the infection of the upper respiratory tract, concretely comprises the following steps：
First, in pharmaceutical grade clean area, trilobatin, aspirin, β-acetoxyl group isoamyl are weighed by above-mentioned metering ratio
The gloomy glycosides B of acyl Alkannin, cefathiamidine, allicin, Bali, pot marigold glycosides E, Swertianolin, donaxine, loose ester alcohol glucosulfone
Glycosides, sieving, machinery adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, is pressed after mixing
Piece and low temperature drying, at 8 DEG C, packaging obtains final product the Western medicine compound of the treatment infection of the upper respiratory tract to temperature control.
Pharmacology test
1st, acute toxicity test
It is experiment with Western medicine compound obtained in the embodiment of the present invention 3, using gastric infusion mode, is continuously given in 24h
Medicine 3 times, per minor tick 6h, is administered 240mg/kg doses every time, and daily accumulation medicine total amount reaches 720mg medicines/kg, equivalent to people
60 times of quantity.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, hair color light, its average body
Weight increases with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain,
Thymus gland, stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：West of the invention
Drug composition is without acute toxic reaction.
2nd, long term toxicity test
It is experiment with Western medicine compound obtained in the embodiment of the present invention 3, using gastric infusion mode, by Western medicine group of the present invention
Compound is divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 120,240,360mg medicines/kg/d,
10,20,30 times equivalent to clinical dosage.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematology
Mark, blood parameters without obvious influence, Systematic anatomy, organ coefficient and histopathological examination also no abnormal disease
Reason changes.It is discontinued 2 weeks and also has no substantially change.Result shows：Western medicine compound of the present invention does not find in long term toxicity test
Overt toxicity reacts and delayed toxicity reaction.It can be seen that, Western medicine compound non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical test
Accept totally 200 infection of the upper respiratory tract patients for medical treatment, wherein, male 100, women 100；Give the embodiment of the present invention
3 Western medicine compounds for preparing, according to 12mg/kg/ days, 3 days as one therapeutic course (three courses for the treatment of of treatment) carried out symptom follow-up record；Face
Bed curative effect determinate standard is to cure：Cardinal symptom, sign are wholly or substantially alleviated, and objective indicator recovers normal；It is effective：Mainly
Symptom, sign are relieved, and objective indicator is close to normally；Effectively：Cardinal symptom, sign take a turn for the better, and objective indicator makes moderate progress；Nothing
Effect：Cardinal symptom, sign are unchanged, and objective indicator change substantially or is not aggravated.
Treatment results：200 patients, 144 recoveries from illness, 27 are effective, and 22 are effectively, 7 invalid, total effective rates
96.5%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. a kind of Western medicine compound for treating the infection of the upper respiratory tract, it is characterised in that the primary raw material according to weight portion is：Three leaves
Glucoside 20-30 parts, aspirin 10-15 parts, β -5-13 parts of acetoxyl group isovaleryl Alkannin, cefathiamidine 8-14 parts, allicin
27-35 parts, 6-8 parts of Bali gloomy glycosides B, 4-9 parts of pot marigold glycosides E, Swertianolin 16-19 parts, donaxine 2-6 parts, loose ester alcohol two
Glucoside 2-6 parts.
2. it is according to claim 1 treatment the infection of the upper respiratory tract Western medicine compound, it is characterised in that exhaled in the treatment
The Western medicine compound of road infection is inhaled, is according to the primary raw material of weight portion：Trilobatin 24-27 parts, aspirin 12-15 parts, β-
7-12 parts of acetoxyl group isovaleryl Alkannin, cefathiamidine 10-12 parts, allicin 29-31 parts, 6-8 parts of Bali gloomy glycosides B, golden small cup
4-9 parts of glycosides E of flower, Swertianolin 16-19 parts, donaxine 2-6 parts, loose 2-6 parts of ester alcohol diglucoside.
3. it is according to claim 1 and 2 treatment the infection of the upper respiratory tract Western medicine compound, it is characterised in that the treatment
The Western medicine compound of the infection of the upper respiratory tract, be according to the primary raw material of weight portion：26 parts of trilobatin, 14 parts of aspirin, β-second
10 parts of acyloxy isovaleryl Alkannin, 11 parts of cefathiamidine, 30 parts of allicin, 7 parts of the gloomy glycosides B of Bali, 7 parts of pot marigold glycosides E, when
18 parts of medicine alcohol glucoside, 4 parts of donaxine, loose 4 parts of ester alcohol diglucoside.
4. the preparation method of the Western medicine compound of a kind for the treatment of infection of the upper respiratory tract as described in claim 1-3 is any, it is special
Levy and be, concretely comprise the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh trilobatin, aspirin, β-acetoxyl group isovaleryl Ah
Block peaceful, cefathiamidine, allicin, the gloomy glycosides B of Bali, pot marigold glycosides E, Swertianolin, donaxine, loose ester alcohol diglucoside, mistake
Sieve, machinery adds ultra-pure water after mixing, and places in pharmacy mixer, mixes 4-8min, controls RSD≤5%, and compressing tablet is simultaneously after mixing
Low temperature drying, at 4-8 DEG C, packaging obtains final product the Western medicine compound of the treatment infection of the upper respiratory tract to temperature control.
5. it is according to claim 4 treatment the infection of the upper respiratory tract Western medicine compound preparation method, it is characterised in that tool
Mix 6min in body step.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171805.8A CN106727615A (en) | 2016-12-17 | 2016-12-17 | A kind of Western medicine compound for treating the infection of the upper respiratory tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171805.8A CN106727615A (en) | 2016-12-17 | 2016-12-17 | A kind of Western medicine compound for treating the infection of the upper respiratory tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727615A true CN106727615A (en) | 2017-05-31 |
Family
ID=58892084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611171805.8A Pending CN106727615A (en) | 2016-12-17 | 2016-12-17 | A kind of Western medicine compound for treating the infection of the upper respiratory tract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727615A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634479A (en) * | 2004-03-12 | 2005-07-06 | 诺氏制药（吉林）有限公司 | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof |
| CN1686090A (en) * | 2005-04-18 | 2005-10-26 | 四川科伦药业股份有限公司 | Garlicin injection agent medicine and its preparation method |
| CN104524585A (en) * | 2014-12-08 | 2015-04-22 | 悦康药业集团有限公司 | Cefathiamidine composition |
| CN104688951A (en) * | 2013-12-09 | 2015-06-10 | 鲜丹科 | Medicine for eliminating nasopharyngitis pain |
-
2016
- 2016-12-17 CN CN201611171805.8A patent/CN106727615A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634479A (en) * | 2004-03-12 | 2005-07-06 | 诺氏制药（吉林）有限公司 | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof |
| CN1686090A (en) * | 2005-04-18 | 2005-10-26 | 四川科伦药业股份有限公司 | Garlicin injection agent medicine and its preparation method |
| CN104688951A (en) * | 2013-12-09 | 2015-06-10 | 鲜丹科 | Medicine for eliminating nasopharyngitis pain |
| CN104524585A (en) * | 2014-12-08 | 2015-04-22 | 悦康药业集团有限公司 | Cefathiamidine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083508B (en) | Preparation method of traditional Chinese medicine preparation for preventing and treating respiratory disease caused by chicken airbag inflammation | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN106727615A (en) | A kind of Western medicine compound for treating the infection of the upper respiratory tract | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN106727907A (en) | A kind of Chinese and Western medicine combination for treating viral pneumonia and preparation method thereof | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN106620642A (en) | Western medicine composition for treating hyperglycemia | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN106581274A (en) | Chinese and western medicine composite for treating amygdalitis and preparing method thereof | |
| CN106668600A (en) | Composite preparation for treating chronic glomerulitis | |
| CN106727508A (en) | A kind of combination drug for treating chronic dysentery | |
| CN106581025A (en) | Composite western medicine for treating chronic dysentery | |
| CN106581024A (en) | Western medicine composition for treating hyperlipidemia | |
| CN101244150B (en) | Medicament for treating enteritis | |
| CN106727643A (en) | A kind of Western medicine for treating bacterial pneumonia | |
| CN106619666A (en) | Pharmaceutical composition for treating swine dysentery | |
| CN106727647A (en) | A kind of medicine for treating fatty liver | |
| CN101518606B (en) | Medicament for curing chronic aplastic anemia and preparation method thereof | |
| CN106728768A (en) | It is a kind of to treat Chinese and western medicinal composition of hyperglycaemia and preparation method thereof | |
| CN106692294A (en) | Compound Chinese-Western combination for treating pertussis and preparation method thereof | |
| CN106074565B (en) | A kind of pharmaceutical composition and its application in preparation of anti-tumor drugs containing Sorafenib and micromolecular compound | |
| CN106727786A (en) | A kind of antipyretic of children's Integrated TCM and preparation method thereof | |
| CN106581038A (en) | Asthma treatment medicine | |
| CN104524577A (en) | Method for treating homeopathic ultramicro-traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |